Financial toxicity and cancer treatment costs impact patient adherence, quality of life, and overall health outcomes, according to data detailed by the National Cancer Institute (NCI). Rising out-of-pocket expenses for oncology medications often force patients to skip doses, delay fills, or abandon therapies entirely.
Prescription Copayments and Treatment Nonadherence
According to NCI data, multiple retrospective cohort and cross-sectional studies demonstrate a link between high prescription copayment amounts and reduced patient compliance with cancer therapy. A cross-sectional analysis utilizing data from the 2011 to 2014 National Health Interview Survey revealed that individuals aged 18 to 64 years with a recent or previous cancer diagnosis reported changing their prescription drug use for financial reasons at higher rates than individuals without a cancer history.
Specific targeted therapies show drop-offs in patient persistence when costs rise. Research examining imatinib copayments and medication adherence among chronic myeloid leukemia patients between 2002 and 2011 found that monthly copayments ranged widely from $0 to $4,792. Patients in the highest quantile of monthly copayments faced an adjusted risk ratio of 1.70 for discontinuing imatinib during the first 180 days of treatment compared to those in the lowest quantile, according to NCI-cited findings.
Breast Cancer Therapy Discontinuation Rates
The financial burden extends across multiple malignancies, including breast cancer. Studies evaluating copayment amounts for adjuvant endocrine therapy, aromatase inhibitors, and tamoxifen demonstrated that women facing the highest out-of-pocket costs are less likely to take their cancer-related medications on a daily basis. Over the long term, these financial barriers result in nonpersistence of use.
Patient Distress and Cost Coping Strategies
A cross-sectional survey of 300 adult patients receiving cancer therapy at the Duke Cancer Institute quantified the immediate human toll of these expenses. The survey found that 16% of patients reported high or overwhelming financial distress, 27% reported medication nonadherence, and 4.67% reported chemotherapy nonadherence. Among those reporting medication nonadherence, 14% specified skipping doses to make prescriptions last longer, 11% took smaller amounts than prescribed, and 22% did not fill a prescription at all because of cost.
The Duke Cancer Institute study identified specific risk factors associated with an increased likelihood of nonadherence:
- Previous out-of-pocket cost discussions, showing an adjusted odds ratio of 2.58.
- Higher financial burden than expected, with an adjusted odds ratio of 2.90.
- High financial distress overall, carrying an adjusted odds ratio of 1.64.
Conversely, having private insurance was associated with a statistically significant decreased risk of nonadherence, yielding an adjusted odds ratio of 0.31, according to the NCI data summary.
Clinical Implications and Evidence Gaps
While observational cohort and cross-sectional studies highlight these vulnerabilities, the NCI notes that such study designs remain prone to inherent biases. Currently, no evidence from randomized controlled clinical trials is available to guide patients and physicians specifically on outcomes related to financial toxicity.
Related reading